BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 24096969)

  • 1. Characterization of statin dose response in electronic medical records.
    Wei WQ; Feng Q; Jiang L; Waitara MS; Iwuchukwu OF; Roden DM; Jiang M; Xu H; Krauss RM; Rotter JI; Nickerson DA; Davis RL; Berg RL; Peissig PL; McCarty CA; Wilke RA; Denny JC
    Clin Pharmacol Ther; 2014 Mar; 95(3):331-8. PubMed ID: 24096969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response.
    Voora D; Shah SH; Reed CR; Zhai J; Crosslin DR; Messer C; Salisbury BA; Ginsburg GS
    Circ Cardiovasc Genet; 2008 Dec; 1(2):100-6. PubMed ID: 20031551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LDL-C goal attainment in patients who remain on atorvastatin or switch to equivalent or non-equivalent doses of simvastatin: a retrospective matched cohort study in clinical practice.
    Rublee DA; Burke JP
    Postgrad Med; 2010 Mar; 122(2):16-24. PubMed ID: 20203452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy.
    Becker ML; Visser LE; van Schaik RH; Hofman A; Uitterlinden AG; Stricker BH
    Pharmacoepidemiol Drug Saf; 2010 Jan; 19(1):75-81. PubMed ID: 19802823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug utilization patterns and cardiovascular outcomes in elderly patients newly initiated on atorvastatin or simvastatin.
    Swindle JP; Potash J; Kulakodlu M; Kuznik A; Buikema A
    Am J Geriatr Pharmacother; 2011 Dec; 9(6):471-82. PubMed ID: 22019005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of statins in hypertriglyceridemia.
    Stein EA; Lane M; Laskarzewski P
    Am J Cardiol; 1998 Feb; 81(4A):66B-69B. PubMed ID: 9526817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
    Jones PH; Davidson MH; Stein EA; Bays HE; McKenney JM; Miller E; Cain VA; Blasetto JW;
    Am J Cardiol; 2003 Jul; 92(2):152-60. PubMed ID: 12860216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of lipid-lowering therapy with statins for secondary prevention of atherosclerosis--guidelines vs. reality.
    Bożentowicz-Wikarek M; Kocełak P; Smertka M; Olszanecka-Glinianowicz M; Chudek J
    Pharmacol Rep; 2012; 64(2):377-85. PubMed ID: 22661189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
    Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.
    Pedersen TR; Faergeman O; Kastelein JJ; Olsson AG; Tikkanen MJ; Holme I; Larsen ML; Bendiksen FS; Lindahl C; Szarek M; Tsai J;
    JAMA; 2005 Nov; 294(19):2437-45. PubMed ID: 16287954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population.
    Giannakopoulou E; Ragia G; Kolovou V; Tavridou A; Tselepis AD; Elisaf M; Kolovou G; Manolopoulos VG
    Mol Biol Rep; 2014 Jul; 41(7):4631-8. PubMed ID: 24668570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial.
    Illingworth DR; Crouse JR; Hunninghake DB; Davidson MH; Escobar ID; Stalenhoef AF; Paragh G; Ma PT; Liu M; Melino MR; O'Grady L; Mercuri M; Mitchel YB;
    Curr Med Res Opin; 2001; 17(1):43-50. PubMed ID: 11464446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-response effects of atorvastatin and simvastatin on high-density lipoprotein cholesterol in hypercholesterolaemic patients: a review of five comparative studies.
    Wierzbicki AS; Mikhailidis DP
    Int J Cardiol; 2002 Jul; 84(1):53-7. PubMed ID: 12104065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice.
    Heintjes EM; Penning-van Beest FJ; Plat AW; Meerding WJ; Webb K; Sturkenboom MC; Herings RM
    Pharmacotherapy; 2012 Jul; 32(7):631-41. PubMed ID: 22760692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).
    Bays HE; Dujovne CA; McGovern ME; White TE; Kashyap ML; Hutcheson AG; Crouse JR;
    Am J Cardiol; 2003 Mar; 91(6):667-72. PubMed ID: 12633795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing adherence to statin therapy using patient report, pill count, and an electronic monitoring device.
    Cheng CW; Woo KS; Chan JC; Tomlinson B; You JH
    Am J Health Syst Pharm; 2005 Feb; 62(4):411-5. PubMed ID: 15745895
    [No Abstract]   [Full Text] [Related]  

  • 17. Therapeutic change of HMG-CoA reductase inhibitors in patients with coronary artery disease.
    Hilleman DE; Wurdeman RL; Lenz TL
    Pharmacotherapy; 2001 Apr; 21(4):410-5. PubMed ID: 11310513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study.
    Roeters van Lennep HW; Liem AH; Dunselman PH; Dallinga-Thie GM; Zwinderman AH; Jukema JW
    Curr Med Res Opin; 2008 Mar; 24(3):685-94. PubMed ID: 18226326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of association of the p450 oxidoreductase *28 single nucleotide polymorphism with the lipid-lowering effect of statins in hypercholesterolemic patients.
    Ragia G; Kolovou V; Tavridou A; Elens L; Tselepis AD; Elisaf M; Van Schaik RH; Kolovou G; Manolopoulos VG
    Mol Diagn Ther; 2014 Jun; 18(3):323-31. PubMed ID: 24430948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention.
    Zhou Z; Rahme E; Pilote L
    Am Heart J; 2006 Feb; 151(2):273-81. PubMed ID: 16442888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.